Journal Papers, Abstracts, and Commentaries
| |
Complex Drug Interactions of the HIV Protease
Inhibitors 3: Effect of Simultaneous or Staggered
Dosing of
Digoxin and Ritonavir, Nelfinavir, Rifampin or Bupropion.
Kirby BJ, Collier AC, Kharasch ED,
et al
Drug Metab Dispos.
2011 Dec 21.
Abstract
Influence of drug transport proteins on the pharmacokinetics and
drug interactions of
HIV protease inhibitors.
Griffin L, Annaert P, Brouwer KL.
J Pharm Sci.
2011 Jun 22.
.
Abstract
HIV Protease Inhibitors: Effect on the
Opportunistic Protozoan Parasites.
Alfonso Y, Monzote L.
Open Med Chem J.
2011;5:40-50
Abstract
Characterization of HIV-1 from patients with
virological failure to a boosted protease inhibitor
regimen. Lillemark MR, Gerstoft J, Obel N,
et al
J Med Virol.
2011 Mar;83(3):377-383
Abstract
Comparative Molecular Field Analysis of a
Series of Inhibitors of HIV-1 Protease.
Ferreira LG, Leitão A, Montanari CA, Andricopulo AD.
Med Chem.
2011 Jan 11.
Abstract
HIV protease inhibitors: garlic supplements
and first-pass intestinal metabolism impact on the
therapeutic efficacy.
Berginc K, Trdan T, Trontelj J, Kristl A.
Biopharm Drug Dispos.
2010 Oct 26.
Abstract |
Boosted Protease Inhibitor Monotherapy. What Have We Learnt
after Seven Years
of Research? Pulido F, Matarranz M, Rodríguez-Rivera V, et al
AIDS Rev.
2010 Jul-Sep;12(3):127-134
Abstract |
Human immunodeficiency virus protease inhibitors reduce the
growth of human
tumors via a proteasome-independent block of angiogenesis
and matrix
metalloproteinases.
Toschi E, Sgadari C, Malavasi L, et al
Int J Cancer.
2010 Jul 8
Abstract |
Gag Mutations Can Impact Virological Response to Dual Boosted
Protease Inhibitor Combinations in Antiretroviral Naive HIV Infected
Patients (2 IP - ANRS 127 trial).|
Larrouy L, Chazallon C, Landman R,
et al
Antimicrob Agents Chemother.
2010 May 3
Abstract |
Protease inhibitor-based antiretroviral therapy in treatment-naive
HIV-1-infected patients: the evidence behind the options.
Naggie S, Hicks C.
J Antimicrob Chemother. 2010 Apr 23.
Abstract |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by
reducing CD36
and CPT-I fatty acid transporters.
Richmond SR, Carper MJ, Lei X, et al
Biochim Biophys Acta.
2010 Jan 28.
Abstract |
HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired
lipodystrophy in patients on highly active antiretroviral therapy?|
Goulbourne CN, Vaux DJ.
J Biochem Soc Trans. 2010 Feb;38(Pt
1):292-6.
Abstract |
HIV-1 protease inhibitors. A review for clinicians.
Deeks SG, Smith M, Holodniy M, Kahn JO.
JAMA.
1997 Jan 8;277(2):145-53.
Abstract |
HIV Protease Inhibitors Induce ER Stress and Disrupt Barrier
Integrity in Intestinal
Epithelial Cells. Wu X, Sun L, Zha W, Studer E, et al
Gastroenterology.
2009 Sep 1.
Abstract |
HIV protease inhibitors: recent clinical trials and
recommendations on use.
Fernández-Montero JV, Barreiro P, Soriano V.
Expert Opin Pharmacother.
2009 Jul;10(10):1615-29.
Abstract |
Regulatory issues in developing new HIV protease inhibitors:
risks and benefits.
Struble KA, Chan-Tack KM, Soon GG.
Curr Opin HIV AIDS. 2008
Nov;3(6):676-80.
Abstract |
Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in
Subjects Receiving HAART
During Acute or Early HIV Infection.
Ernstrom KB, Little SJ, Routy JP, et al
J Acquir Immune Defic Syndr.
2009 Feb 3.
Abstract
|
Tolerability and Safety of HIV Protease Inhibitors in Adults.
Sax PE, Kumar P.
J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-1124
Abstract
|
Simplification of antiretroviral treatment--how to sustain success, reduce
toxicity
and
ensure
adherence avoiding PI use.
Barreiro P, Garcia-Benayas T, Soriano V, Gallant
J.
AIDS Rev 2002 Oct-Dec;4(4):233-41
Abstract
Therapeutic drug monitoring of HIV-protease inhibitors to assess
noncompliance.
Hugen PW, Burger DM, Aarnoutse RE,et al|
Ther Drug Monit 2002 Oct;24(5):579-87
Abstract
Factors associated with mortality in human immunodeficiency virus type
1-infected
adults initiating protease inhibitor-containing therapy: role of education
level and of
early transaminase
level elevation (APROCO-ANRS EP11 study).
The Antiproteases
Cohorte Agence Nationale de Recherches sur
le SIDA EP 11 study.Lewden C, Raffi F, Cuzin L, et al
J Infect Dis 2002 Sep
1;186(5):710-4
Abstract
|
|
|